FibroGen, Inc.


After the markets closed on April 6, 2021, FibroGen admitted that prior disclosures regarding its safety analyses from the roxadustat Phase 3 program included post-hoc changes to the stratification factors. FibroGen said it would conduct a “comprehensive internal review to ensure” that such errors do not occur again. On this news, FibroGen’s shares fell $14.90 per share, or approximately 43%, to close at just $19.74 per share on April 7, 2021.

Lead Plaintiff deadline
June 11, 2021
class period
November 8, 2019
April 6, 2021
Case Documents
No documents available. Contact us if you need a case document.